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Abstract
Objective To assess the effectiveness of adenoidectomy in children
with recurrent upper respiratory tract infections.
Design Open randomised controlled trial.
Setting 11 general hospitals and two academic centres.
Participants 111 children aged 1-6 with recurrent upper respiratory tract
infections selected for adenoidectomy.
Intervention A strategy of immediate adenoidectomy with or without
myringotomy or a strategy of initial watchful waiting.
Main outcome measure Primary outcome measure: number of upper
respiratory tract infections per person year calculated from data obtained
during the total follow-up (maximum 24 months). Secondary outcome
measures: days with upper respiratory tract infection per person year,
middle ear complaints with fever in episodes and days, days with fever,
prevalence of upper respiratory tract infections, and health related quality
of life.
Results During the median follow-up of 24 months, there were 7.91
episodes of upper respiratory tract infections per person year in the
adenoidectomy group and 7.84 in the watchful waiting group (difference
in incidence rate 0.07, 95% confidence interval −0.70 to 0.85). No
relevant differences were found for days of upper respiratory tract
infections and middle ear complaints with fever in episodes and days,
nor for health related quality of life. The prevalence of upper respiratory
tract infections decreased over time in both groups. Children in the
adenoidectomy group had significantly more days with fever than the
children in the watchful waiting group. Two children had complications
related to surgery.
Conclusion In children selected for adenoidectomy for recurrent upper
respiratory tract infections, a strategy of immediate surgery confers no
clinical benefits over a strategy of initial watchful waiting.
Trial registration Dutch Trial Register NTR968: ISRCTN03720485.
Introduction
An acute upper respiratory tract infection is the most common
diagnosis in children in primary care: every year the diagnosis
is made in one in every two children aged 0-4 and in one in 10
of those aged 5-9.
1 The true incidence of the condition in the
community is much higher as usually parents do not consult
theirdoctorwhentheirchilddevelopsanupperrespiratorytract
infection. Upper respiratory tract infections not only affect
children’s health but also account for a large proportion of
annual healthcare expenditure and high indirect costs for the
family and society.
2-4
An estimated 20% of children experience recurrent upper
respiratory tract infections, and many of these children are
referred to the ear, nose, and throat surgeon for surgery.
5-8
Adenoidectomyisoneofthemostcommonlyperformedsurgical
procedures in children in western countries. In 2009 in the
Netherlands15179children(16.3per1000)aged0-4and5573
children (5.5 per 1000) aged 5-9 underwent adenoidectomy.
9 10
In 60% of these children, recurrent upper respiratory tract
infectionsweretheindicationforsurgery.
11In2006intheUnited
States 129 540 children (1.76 per 1000) up to the age of 18
underwent adenoidectomy. In 12% of these children the
operation was performed because of chronic infections.
12 In
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RESEARCHboth countries the figures have remained stable over the past
decade.
12 13
Remarkably, the adenoidectomy rate is more than three times
higher in the Netherlands than in the US, and the proportion of
children operated on for infections varies fivefold across these
twocountries,suggestingthatthereisnointernationalconsensus
as to which children benefit from the operation.
Evidence for the effectiveness of adenoidectomy in children
withrecurrentupperrespiratorytractinfectionsisindeedscarce
and (inter)nationally accepted guidelines are lacking. In our
recent Cochrane review we showed that so far only two
randomised controlled trials of adenoidectomy in children
included upper respiratory tract infections as an outcome
measure.
14 One study was methodologically weak,
15 and the
otherwasperformedinchildrenwithrecurrentacuteotitismedia
rather than upper respiratory tract infections.
16 In this open
multicentre randomised controlled trial we studied the
effectivenessofadenoidectomyinchildrenwithrecurrentupper
respiratory tract infections.
Methods
Patients
We performed an open multicentre randomised controlled trial
between April 2007 and October 2010. Ear, nose, and throat
surgeonsin11generalhospitalsandtwoacademiccentreswere
asked to complete a questionnaire on their patients aged 1-6
whom they selected for adenoidectomy with or without
myringotomy. They were asked to list the indication for the
operationandanypreviousear,nose,andthroatsurgery.Parents
who had expressed interest in the trial were contacted by a
memberofourstudyteam.Childrenwereeligibletoparticipate
inthetrialiftheywereselectedforadenoidectomyforrecurrent
upper respiratory tract infections. The parents were given
detailed information about the trial, exclusion criteria were
checked, and a standard demographic and disease specific
questionnaire was completed. We excluded children who had
previously undergone adenoidectomy or adenotonsillectomy
and those with tympanostomy tubes (grommets) or who had an
indication for insertion of tympanostomy tubes. We also
excluded children with Down’s syndrome and craniofacial
malformation.
Randomisation
Children whose parents gave informed consent were randomly
assignedtooneoftwostrategies:adenoidectomywithorwithout
myringotomy within six weeks or initial watchful waiting. For
thispurposeweusedacomputerisedminimisationstrategy—that
is, a method of ensuring balance between prognostic factors in
small samples
17; factors that were taken into account were age
(<2 and ≥2) and hospital. Treatment allocation was concealed
until formal informed consent was obtained and the child was
included in the trial.
Baseline measurements
When children entered the study, the study doctor filled in a
demographic and disease specific questionnaire including
information on the number of upper respiratory tract infections
in the year before trial entry, previous ear, nose, and throat
operations,andriskfactorsforupperrespiratorytractinfections.
Parents filled in two generic and three disease specific
questionnaires on health related quality of life: the child health
questionnaire,
18 19 the RAND general health rating index for
children,
20 21thesinonasalsymptomsquestionnaire,
22theOSA-18
quality of life questionnaire,
23 and the otitis media-6
questionnaire.
24 All children underwent an ear, nose, and throat
examinationincludingfibreopticendoscopyofthenasopharynx.
Adenoidsizewasgradedasobstructingthechoanaefor0-25%,
26-50%, 51-75%, or 76-100%. A blood sample was taken for
the Phadiatop test, an allergen specific IgE test to a panel of
common food and aeroallergens in children, with the result
classified as positive or negative. Finally, data on
nasopharyngeal flora, exhaled nitric oxide, and costs were
collected at baseline and during follow-up. These results will
be reported separately.
Follow-up
During the two year follow-up parents kept a diary, including
specific symptoms of upper respiratory tract infections: nasal
stuffiness,mouthbreathing,nasaldischarge,sorethroat,cough,
and fever. They also noted middle ear complaints and absence
from day care or school because of upper respiratory tract
infections. They measured their child’s temperature every day
with a validated tympanic membrane thermometer. To avoid
information bias, we had an electronic device built in, which
stored date and first temperature measurement of each day.
25
The study doctor collected the diary and thermometer data
during the follow-up visits at 3, 6, 12, 18, and 24 months and
examined the child’s ears, nose, and throat. At those visits
parents also filled in questionnaires on health related quality of
life.
Parents,generalpractitioners,andear,nose,andthroatsurgeons
of the participating children were encouraged to manage upper
respiratory tract infections during follow-up according to their
regular practice.
Primary and secondary outcomes
The primary outcome measure was the number of upper
respiratorytractinfectionsperpersonyearcalculatedfromdata
obtainedduringfollow-up(maximum24months).Thedefinition
of upper respiratory tract infection was two or more of the
following: fever (a temperature of 38°C or higher as measured
by a tympanic thermometer), diary scored symptoms of nasal
stuffiness or mouth breathing, nasal discharge, sore throat, or
cough. An episode ended when the child was free from
symptoms for at least a day. A new episode was recorded after
at least seven days without symptoms or fever.
Secondaryoutcomemeasuresweredayswithupperrespiratory
tract infection per person year, incidences of mild and severe
upperrespiratorytractinfection,andmiddleearcomplaintswith
fever in episodes and days, days with fever, days of absence
from day care or school because of upper respiratory tract
infection, prevalence of upper respiratory tract infections, and
health related quality of life. Mild upper respiratory tract
infectionwasdefinedasaninfectionwithoutfeverandresolving
within 10 days. Severe upper respiratory tract infection was
defined as an infection persisting for more than 10 days or an
infection accompanied by fever. Middle ear complaints were
defined as acute otorrhoea, earache, or pulling the ear
accompanied by fever. To measure the burden of upper
respiratory tract infections during follow-up we calculated the
prevalence of upper respiratory tract infections per week.
Generichealthrelatedqualityoflifewasassessedwiththechild
health questionnaire
18 19 and the RAND general health rating
index for children
20 21 and disease specific health related quality
oflifewiththesinonasalsymptomsquestionnaire,
22theOSA-18
quality of life questionnaire,
23 and the otitis media-6
questionnaire.
24
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RESEARCHStatistical analysis
Our sample size calculation was based on a clinically relevant
reductionofupperrespiratorytractinfectionsof33%.Assuming
a mean baseline incidence of six (SD three) upper respiratory
tract infections each year, and taking α=0.05 and a power of
0.90, we calculated that we would need 49 children in each
group. To allow for 10% loss to follow-up we aimed to include
110 children.
Theeffectsofadenoidectomyonupperrespiratorytractinfection
episodes and days were calculated as differences in incidence
rates and incidence rate ratios per person year with 95%
confidence intervals. Scores on health related quality of life
instruments were linearly transformed into 0-100 scales (100
being the best possible score) and presented per subscale. We
used Student’s t tests or Mann-Whitney U tests to evaluate
differencesbetweenthetwogroups.Poissonregressionanalyses
with a robust covariance matrix estimator were used to adjust
for potential confounding (observed baseline differences in
prognostic factors, such as sex, breast feeding for more than
threemonths,familyhistoryofupperrespiratorytractinfections,
and passive smoking). The 95% confidence intervals of the
adjusted rate differences and ratios were addressed in R by
meansofbootstrapping,forwhichwereplicatedthetrial10000
times using random replacement samples.
Potential modification of the effect of adenoidectomy was
evaluatedwithPoissonanalysesincludinginteractiontermsfor
age (<2 and ≥2), adenoid size (≤75% v >75% obstruction of
the choanae), and Phadiatop (positive v negative). Subgroups
were further analysed only in case of significant interaction
effects.
In addition to the intention to treat analysis, we also performed
two sensitivity analyses: a per protocol analysis in which we
excluded the children in the watchful waiting group who went
ontohavesurgery,andanastreatedanalysisinwhichweadded
the children in the watchful waiting group who underwent
surgery to the adenoidectomy group.
To study the external validity, we compared demographic and
disease specific characteristics of the included children with
thosewhowereeligibletoparticipatebutwhoseparentsdidnot
give informed consent. We used Pearson’s χ
2 tests to compare
these characteristics.
All analyses were performed according to the intention to treat
principlewithSPSSversion17(SPSS,Chicago,IL),Rothman’s
Episheet (11 June 2008), and R version 2.13.0 (13 April 2011).
Results
Patients
Between April 2007 and April 2009, 373 children aged 1-6
selectedforadenoidectomyforrecurrentupperrespiratorytract
infections were referred to our trial centre. Of these, 262 (70%)
were ineligible or excluded for various reasons (fig 1⇓), and
111wererandomlyassignedtooneoftwostrategies:54children
to adenoidectomy with or without myringotomy within six
weeks and 57 children to initial watchful waiting.
Table 1 shows the baseline characteristics.⇓ The mean age was
36 and 38 months and the median number of upper respiratory
tract infection episodes in the year before trial entry was 10 in
theadenoidectomygroupandnineinthewatchfulwaitinggroup.
Median follow-up was 24 months in both groups.
Duringthetrialperiod,11(10%)childrenwerelosttofollow-up
for non-medical reasons: four (7%) from the adenoidectomy
group and seven (12%) from the watchful waiting group. All
children allocated to adenoidectomy underwent surgery within
six weeks: 48 (89%) had adenoidectomy alone and six (11%)
hadadenoidectomyandmyringotomy.Duringfollow-upseven
(13%) children allocated to adenoidectomy underwent
tonsillectomy and revision adenoidectomy and three (6%) had
tympanostomy tubes inserted. During follow-up 23 (40%)
childrenallocatedtowatchfulwaitingunderwentfurthersurgery.
Seventeen underwent adenoidectomy (in 11 (19%) it was
adenoidectomy only; in four (7%) it was combined with
myringotomy and in two (4%) with tympanostomy tubes; one
(2%)childunderwentadenoidectomyat12monthsandrevision
adenoidectomy with tympanostomy tubes at 24 months, one
(2%)underwentadenoidectomyatsixmonthsandtonsillectomy
at 12 months). Six (11%) underwent adenotonsillectomy (in
one combined with myringotomy).
Primary outcome
During the total follow-up the incidences of upper respiratory
tract infections episodes in the adenoidectomy and watchful
waiting group were 7.91 and 7.84 per person year (difference
in incidence rate 0.07, 95% confidence interval −0.70 to 0.85;
table 2⇓). These incidences were 9.22 and 9.39 per person year
(difference −0.17, −1.34 to 1.00), respectively, during the first
year of follow-up and 6.55 and 6.17 per person year (difference
0.37, −0.62 to 1.37), respectively, during the second year of
follow-up(table3⇓).Similarresultswerefoundafteradjustment
for observed baseline differences—that is, the adjusted rate
differences for the total follow-up, year one, and year two were
−0.03 (−1.72 to 1.67), −0.14 (−1.76 to 1.68), and 0.13 (−2.05
to 2.32) (table 4⇓).
Secondary outcomes
Duringthetotalfollow-uptherewere66.10and67.36dayswith
upper respiratory tract infection per person year (difference in
incidence rate −1.27, −3.52 to 0.99; table 2⇓) in the
adenoidectomy and watchful waiting group, respectively.
Figure 2⇓ shows that the proportion of children with an upper
respiratorytractinfection(expressedastheprevalenceperweek)
decreased over time in both groups. No differences were found
between the two groups for episodes of mild and severe upper
respiratory tract infection and days per person year during the
totalfollow-up(table2⇓).Childrenintheadenoidectomygroup
had significantly more days with fever than the children in the
watchful waiting group: 20.00 v 16.49 days per person year
during the total follow-up (difference 3.51, 2.33 to 4.69).
During the total follow-up there were 0.51 episodes of middle
earcomplaintswithfeverperpersonyearintheadenoidectomy
group and 0.45 in the watchful waiting group (difference 0.05,
−0.14 to 0.24 (table 2⇓). Children in the adenoidectomy group
had 0.86 days per person year of middle ear complaints with
feverandchildreninthewatchfulwaitinggrouphad0.85(0.01,
−0.24to0.27).Daysofabsencefromdaycareorschoolbecause
ofanupperrespiratorytractinfectionwere1.66and2.00(−0.33,
−0.71 to 0.04) in the adenoidectomy and watchful waiting
groups, respectively. Table 3⇓ shows the results for follow-up
year one and two separately. After adjustment for observed
baseline differences, we found no significant differences (table
4⇓).
Health related quality of life as measured by generic (child
health questionnaire,
18 19 and RAND
20 21) and disease specific
(sinonasal symptoms questionnaire,
22 OSA-18 quality of life
questionnaire,
23 and otitis media-6 questionnaire.
24)
questionnaires,didnotdiffersignificantlybetweenbothgroups
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5154 doi: 10.1136/bmj.d5154 Page 3 of 13
RESEARCHover time. Exact numbers are available in appendix 1 on
bmj.com).
Aswefoundnosignificantinteractionterms,wedidnotfurther
analyse any subgroups of patients.
Crossovers
We found no significant differences in baseline variables nor
in the number of upper respiratory tract infections during the
first year of follow-up between those children in the control
group who did and did not cross over (data not shown).
The per protocol and as treated analyses (table 5⇓) yielded the
same results as the intention to treat analysis regarding our
primary outcome—that is, upper respiratory tract infection
episodesduringthetotalfollow-up.Forexample,thedifference
inincidencerateforepisodesofupperrespiratorytractinfection
was −0.13 (−1.02 to 0.77) for the per protocol analysis and
−0.23 (−1.08 to 0.62) for the as treated analysis. The adjusted
incidenceratedifferencesalsoshowednosignificantdifferences
for the primary outcome (table 6).⇓
Generalisability
To assess the external validity of our results we compared
demographicanddiseasespecificcharacteristicsofthechildren
participating in the trial with those of the 165 (60%) children
whowereeligibleforthetrialbutdidnotparticipateforvarious
reasons. In the trial participants and eligible but
non-participatingchildren,respectively,themeanageatreferral
was 36 and 34 months, 59% and 56% were boys, 57% and 45%
had symptoms of snoring or obstructive apnoea, 78% and 84%
had nasal discharge on examination, and 67% and 69% had
nasal obstruction on examination. Importantly, none of these
variables differed significantly.
Adverse events
Two (4%) children in the adenoidectomy group experienced an
adverse event: one child was admitted to hospital for an asthma
exacerbation during follow-up and in one child a primary tooth
was broken when the mouth gag was inserted. One (2%) child
in the watchful waiting group who underwent
adenotonsillectomy during follow-up was admitted to hospital
for a postoperative haemorrhage.
Discussion
In children selected for adenoidectomy for recurrent upper
respiratory tract infections, a strategy of immediate surgery did
not reduce the number of upper respiratory tract infections
compared with a strategy of initial watchful waiting. The
prevalence of upper respiratory tract infections decreased
similarly over time in both groups, suggesting that the
contributionofsurgerytothefavourablenaturalcourseofupper
respiratory tract infections is trivial.
We found no relevant differences between the two strategies
for days of upper respiratory tract infections, days and episodes
ofmildandsevereupperrespiratorytractinfectionsandmiddle
ear complaints with fever, days of absence from day care or
school,andhealthrelatedqualityoflife.Therewasasignificant
difference for days with fever.
Forty per cent of children in the initial watchful waiting group
underwentsurgeryduringthecourseofthetrial.Thesechildren,
however, were not more severely affected by upper respiratory
tract infections than the 60% who did not undergo surgery nor
did they do better after surgery.
Comparison with literature
So far, most trials of adenoidectomy have been performed in
children with recurrent acute otitis media or persistent otitis
mediawitheffusionandotitismediawasstudiedastheprimary
outcome. These studies showed a benefit of adenoidectomy
regarding the resolution of middle ear effusion and also a small
benefitregardinghearingbutdidnotobserveabeneficialeffect
on recurrence of acute otitis media.
26
The one study (n=76) that did include children selected for
adenoidectomy because of frequent upper respiratory tract
infectionsshowedthatat12months’follow-up75%ofchildren
in the adenoidectomy group and 73% of children in the control
groupimprovedduringfollow-upregardingcommoncolds(risk
difference 2%, 95% confidence interval −18% to 22%). At 24
months’ follow-up these figures were 77% and 88%,
respectively (−11%, −28% to 7%).
15 Another study (n=180) of
adenoidectomyversuschemoprophylaxisandplaceboinchildren
with recurrent acute otitis media included days with rhinitis as
asecondaryoutcome.Childrenintheadenoidectomygrouphad
four fewer days with rhinitis during six months of follow-up
than those in the control groups (95% confidence interval −13
to 7 days).
16
All trials of adenoidectomy performed so far have had
methodologicallimitations.
14 26Firstly,onlythreetrialsprovided
a power analysis and included adequate numbers. As the other
trials included relatively few patients, their power might have
been too low, leading to a type II error. Secondly, most studies
had significant loss to follow-up. This can be associated with
either good or poor outcome. Thirdly, three studies were
analysed per protocol rather than by intention to treat. Per
protocol analyses underestimate the treatment effect as in
surgical trials only children in the watchful waiting group with
persisting complaints can change treatment group, whereas
children of the surgical group, who might experience similar
complaints, cannot change treatment group. Fourthly,
information bias might have been considerable because trials
on adenoidectomy, as most surgical trials, cannot be performed
in a true double blind fashion. Such bias will overestimate the
effect of the intervention. None of the trials tried to minimise
information bias by choosing an objective outcome measure,
such as fever. Finally, the generalisability of the trials can be
questioned as only a small proportion of children undergoing
adenoidectomy were included in the trials.
Possible limitations
Our trial has several limitations. Firstly, we emphasise that we
compared two strategies (immediate adenoidectomy or initial
watchful waiting). As in other surgical trials, such as our
previous study on adenotonsillectomy,
27 the fact that some
patients in the surgery group undergo additional surgical
interventions and some patients in the watchful waiting group
eventually undergo adenoidectomy mimics daily practice.
28 29
This is part of the two strategies we compared. We studied
whether the children in the control group who went on to
undergoadenoidectomyweremoreseverelyaffectedthanthose
who did not. There were no significant differences in baseline
variablesnorinthenumberofupperrespiratorytractinfections
during the first year of follow-up between those children in the
control group who did and did not cross over (data not shown).
Furthermore, the per protocol and as treated analyses yielded
the same results as the intention to treat analysis regarding our
primaryoutcome—thatis,thenumberofupperrespiratorytract
infections during the total follow-up.
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RESEARCHSecondly, we chose 33% as indicating a clinically relevant
difference (in absolute terms a decrease from six to four upper
respiratory tract infections a year) as the incidence of upper
respiratory tract infections in young children is high and is
known to decrease over time spontaneously. Nevertheless, we
looked into the probability that, given our results, a difference
of 20-25%—that is, a difference of 1.5 upper respiratory tract
infections a year—could have occurred. Looking at the
confidence interval of the total follow-up, the value −1.5 is not
within the 99% confidence interval, which means that we can
alsoconfidentlyruleoutadifferenceof1.5episodes.Therefore,
it seems unlikely that the results and conclusions would change
if we had chosen another clinically relevant difference in our
power calculation.
Thirdly, we question whether our results are generalisable to
allchildrenwithrecurrentupperrespiratorytractinfections.As
wefoundnostatisticaldifferencesbetweenthetrialparticipants
andthoseeligiblebutnon-participating,andnoneofthestudied
characteristics modified the effect of adenoidectomy, we think
that these results are generalisable to all children selected for
adenoidectomy for recurrent upper respiratory tract infections.
Strengths of the study
As our randomised controlled trial of adenoidectomy focused
on children with recurrent upper respiratory tract infections, it
provides important evidence for the many children selected for
adenoidectomy for this indication. To our knowledge this is the
first randomised controlled trial focusing specifically on these
children. We included an objective method to study the effect
ofadenoidectomy—thatis,fevermeasureddailybyavalidated
thermometer that automatically stored data. Fever is an
important physical sign in childhood infections, and most
episodes of fever in young children aged under 8 are related to
upper respiratory tract infections.
30 31
For the randomisation process we applied a minimisation
strategythataccountedforageandhospital.Assuch,weensured
that the children within each centre were equally distributed
over the two groups. Therefore potential bias from possible
differencesin“traditions”oftreatingthesechildrenisprecluded.
Conclusion
In children selected for adenoidectomy for recurrent upper
respiratory tract infections, a strategy of immediate surgery
confers no clinical benefits over a strategy of initial watchful
waiting.
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RESEARCHTables
Table 1| Baseline characteristics of 111 children with recurrent upper respiratory tract infections according to treatment allocation. Figures
are numbers (percentage) unless stated otherwise
Watchful waiting (n=57) Adenoidectomy (n=54)
Patients’ characteristics
38 (18) 36 (19) Mean (SD) age (months)
29 (51) 37 (69) Boys
32 (56) 24 (44) Breast fed ≥3 months
16 (30) 12 (24) Positive result on Phadiatop test*
41 (72) 31 (57) Family history for recurrent URTIs
13 (23) 19 (35) Exposure to household nicotine smoke
36 (63) 33 (61) Children with household pets
38 (67) 42 (78) Children with siblings
Education level of mother:
9 (16) 10 (9) Low
30 (53) 22 (41) Average
18 (32) 22 (41) High
36 (88) 33 (81) Day care attendance aged <4 years
Disease characteristics
9 (2 to 17) 10 (3 to 17) Median No of episodes of URTI in year before trial entry (IQR)
−1.70 (−2.42 to 0.42) −0.99 (−2.41 to 1.13) Median (IQR) OSA score†
11 (23) 13 (26) Adenoid size 76-100%
IQR=interquartile range; URTI=upper respiratory tract infection; OSA=obstructive sleep apnoea.
*Allergen specific IgE test to panel of common food and aeroallergens.
†Brouilette OSA score: 1.42×difficulty breathing+1.41×apnoea+0.71×snoring–3.83. Range −3.83-3.5. Score >3.5 is highly predictive of OSA; score −1-3.5 indicates
possible OSA; and score <−1 indicates no OSA.
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RESEARCHTable 2| Primary and secondary outcomes for total follow-up (maximum 24 months) in children with recurrent upper respiratory tract
infections according to treatment allocation
Incidence rate ratio (95% CI) Difference in incidence rate (95% CI)
Watchful waiting (101
person years)
Adenoidectomy (101
person years)
Primary outcome:
1.01 (0.91 to 1.11) 0.07 (−0.70 to 0.85) 7.84 7.91 URTI episodes
Secondary outcomes:
0.98 (0.95 to 1.01) −1.27 (−3.52 to 0.99) 67.36 66.10 URTI days
1.13 (0.98 to 1.30) 0.45 (−0.08 to 0.99) 3.53 3.98 Severe URTI episodes
1.03 (0.99 to 1.08) 1.55 (−0.35 to 3.44) 46.56 48.11 Severe URTI days
0.91 (0.80 to 1.04) −0.38 (−0.94 to 0.18) 4.31 3.93 Mild URTI episodes
0.86 (0.81 to 0.92) −2.81 (−4.03 to −1.60) 20.80 17.99 Mild URTI days
1.21 (1.14 to 1.29) 3.51 (2.33 to 4.69) 16.49 20.00 Fever days
1.11 (0.75 to 1.65) 0.05 (−0.14 to 0.24) 0.45 0.51 Middle ear complaints with fever
episodes
1.01 (0.75 to 1.36) 0.01 (−0.24 to 0.27) 0.85 0.86 Middle ear complaints with fever
days
0.83 (0.68 to 1.02) −0.33 (−0.71 to 0.04) 2.00 1.66 Absence from day care or school
URTI=upper respiratory tract infection.
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RESEARCHTable 3| Primary and secondary outcomes for follow-up at year 1 and year 2 separately in children with recurrent upper respiratory tract
infections according to treatment allocation
Incidence rate ratio (95% CI) Difference in incidence rate (95% CI) Watchful waiting Adenoidectomy
Year 1*
Primary outcome:
0.98 (0.87 to 1.11) −0.17 (−1.34 to 1.00) 9.39 9.22 URTI episodes
Secondary outcomes:
1.16 (1.09 to 1.22) 7.03 (4.35 to 9.71) 45.22 52.24 URTI days
1.06 (0.88 to 1.27) 0.25 (−0.55 to 1.05) 4.23 4.47 Severe URTI episodes
1.25 (1.17 to 1.33) 7.78 (5.50 to 10.06) 31.39 39.17 Severe URTI days
0.92 (0.77 to 1.09) −0.42 (−1.27 to 0.44) 5.16 4.74 Mild URTI episodes
0.95 (0.85 to 1.05) −0.75 (−2.16 to 0.66) 13.82 13.07 Mild URTI days
1.26 (1.15 to 1.38) 4.27 (2.61 to 5.93) 16.51 20.78 Fever days
1.24 (0.75 to 2.07) 0.12 (−0.17 to 0.42) 0.51 0.64 Middle ear complaints with fever episodes
1.15 (0.77 to 1.71) 0.13 (−0.24 to 0.50) 0.88 1.01 Middle ear complaints with fever days
0.83 (0.58 to 1.17) −0.23 (−0.65 to 0.19) 1.33 1.10 Absence from day care or school
Year 2†
Primary outcome:
1.06 (0.91 to 1.24) 0.37 (−0.62 to 1.37) 6.17 6.55 URTI episodes
Secondary outcomes:
0.88 (0.85 to 0.92) −10.71 (−14.38 to −7.03) 91.31 80.60 URTI days
1.25 (1.00 to 1.56) 0.69 (−0.01 to 1.39) 2.78 3.47 Severe URTI episodes
0.91 (0.87 to 0.96) −5.50 (−8.57 to −2.42) 62.96 57.47 Severe URTI days
0.91 (0.73 to 1.13) −0.31 (−1.03 to 0.40) 3.40 3.08 Mild URTI episodes
0.82 (0.75 to 0.88) −5.21 (−7.22 to −3.20) 28.34 23.14 Mild URTI days
1.16 (1.06 to 1.28) 2.72 (1.04 to 4.39) 16.47 19.18 Fever days
0.93 (0.49 to 1.78) −0.03 (−0.27 to 0.22) 0.39 0.36 Middle ear complaints with fever episodes
0.86 (0.55 to 1.36) −0.11 (−0.46 to 0.23) 0.82 0.71 Middle ear complaints with fever days
0.83 (0.64 to 1.07) −0.47 (−1.09 to 0.16) 2.72 2.25 Absence from day care or school
URTI=upper respiratory tract infection.
*52 person years in adenoidectomy group, 53 in watchful waiting group.
†49 person years in each group.
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RESEARCHTable 4| Primary and secondary outcomes in children with recurrent upper respiratory tract infections according to treatment allocation
adjusted for observed differences at baseline
Adjusted incidence rate ratio Adjusted difference in incidence rate (95%
CI)
Watchful waiting Adenoidectomy
Total follow-up*
Primary outcome:
1.00 (0.80 to 1.23) −0.03 (−1.72 to 1.67) 7.89 7.86 URTI episodes
Secondary outcomes:
0.99 (0.73 to 1.31) −0.95 (−20.50 to 4.48) 67.20 66.25 URTI days
1.12 (0.84 to 1.48) 0.42 (−0.63 to 1.52) 3.54 3.97 Severe URTI episodes
1.05 (0.71 to 1.52) 2.28 (−15.62 to 20.17) 46.20 48.49 Severe URTI days
0.89 (0.73 to 1.09) −0.46 (−1.31 to 0.35) 4.35 3.89 Mild URTI episodes
0.85 (0.66 to 1.06) −3.21 (−7.85 to 1.17) 21.01 17.80 Mild URTI days
1.23 (0.68 to 2.12) 3.80 (−6.75 to 14.20) 16.36 20.16 Fever days
1.20 (0.56 to 2.36) 0.09 (−0.26 to 0.43) 0.44 0.53 Middle ear complaints with fever episodes
1.13 (0.48 to 2.60) 0.10 (−0.61 to 0.77) 0.81 0.91 Middle ear complaints with fever days
0.92 (0.64 to 1.30) −0.15 (−0.78 to 0.48) 1.90 1.75 Absence from day care or school
Year 1†
Primary outcome:
0.99 (0.82 to 1.20) −0.14 (−1.76 to 1.68) 9.37 9.23 URTI episodes
Secondary outcomes:
1.15 (0.74 to 1.72) 6.97 (−13.24 to 27.51) 45.24 52.21 URTI days
1.10 (0.85 to 1.40) 0.40 (−0.68 to 1.48) 4.16 4.55 Severe URTI episodes
1.25 (0.71 to 2.13) 7.79 (−11.19 to 26.89) 31.39 39.18 Severe URTI days
0.90 (0.72 to 1.10) −0.55 (−1.62 to 0.48) 5.23 4.68 Mild URTI episodes
0.94 (0.68 to 1.28) −0.83 (−5.10 to 3.28) 13.86 13.03 Mild URTI days
1.25 (0.49 to 2.66) 4.13 (−10.99 to 18.38) 16.57 20.70 Fever days
1.41 (0.60 to 3.07) 0.20 (−0.28 to 0.67) 0.48 0.68 Middle ear complaints with fever episodes
1.34 (0.49 to 3.61) 0.28 (−0.66 to 1.18) 0.81 1.09 Middle ear complaints with fever days
0.99 (0.57 to 1.63) −0.01 (−0.64 to 0.61) 1.22 1.21 Absence from day care or school
Year 2‡
Primary outcome:
1.02 (0.71 to 1.42) 0.13 (−2.05 to 2.32) 6.30 6.43 URTI episodes
Secondary outcomes:
0.89 (0.67 to 1.16) −9.79 (−35.55 to 12.91) 89.39 79.60 URTI days
1.16 (0.71 to 1.82) 0.47 (−0.98 to 1.93) 2.88 3.34 Severe URTI episodes
0.93 (0.64 to 1.32) −4.57 (−26.06 to 16.37) 61.70 57.13 Severe URTI days
0.90 (0.66 to 1.23) −0.32 (−1.35 to 0.65) 3.40 3.08 Mild URTI episodes
0.82 (0.61 to 1.05) −5.10 (−11.86 to 1.39) 27.64 22.54 Mild URTI days
1.20 (0.73 to 1.94) 3.20 (−5.09 to 12.05) 15.81 19.01 Fever days
0.87 (0.18 to 2.08) −0.05 (−0.44 to 0.33) 0.41 0.35 Middle ear complaints with fever episodes
0.86 (0.18 to 2.27) −0.11 (−0.98 to 0.69) 0.82 0.71 Middle ear complaints with fever days
0.90 (0.59 to 1.35) −0.26 (−1.24 to 0.73) 2.57 2.31 Absence from day care or school
URTI=upper respiratory tract infection.
*101 person years in each group.
†52 person years in adenoidectomy group, 53 in watchful waiting group.
‡49 person years in each group.
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RESEARCHTable 5| Results for per protocol and as treated analyses for full follow-up period (maximum 24 months) in children with recurrent upper
respiratory tract infections
Incidence rate ratio (95% CI) Difference in incidence rate (95% CI) Watchful waiting Adenoidectomy
Per protocol*
Primary outcome:
0.98 (0.88 to 1.10) −0.13 (−1.02 to 0.77) 8.04 7.91 URTI episodes
Secondary outcomes:
1.15 (1.10 to 1.19) 8.47 (5.99 to 10.95) 57.63 66.10 URTI days
1.14 (0.96 to 1.34) 0.48 (−0.13 to 1.09) 3.50 3.98 Severe URTI episodes
1.36 (1.29 to 1.43) 12.69 (10.67 to 14.70) 35.42 48.11 Severe URTI days
0.87 (0.74 to 1.01) −0.60 (−1.26 to 0.06) 4.54 3.93 Mild URTI episodes
0.81 (0.76 to 0.87) −4.22 (−5.66 to −2.77) 22.21 17.99 Mild URTI days
1.32 (1.22 to 1.43) 4.88 (3.58 to 6.19) 15.11 20.00 Fever days
1.10 (0.69 to 1.75) 0.05 (−0.17 to 0.27) 0.46 0.51 Middle ear complaints with fever episodes
0.89 (0.63 to 1.26) −0.10 (−0.39 to 0.19) 0.87 0.86 Middle ear complaints with fever days
0.91 (0.71 to 1.15) −0.17 (−0.59 to 0.25) 1.83 1.66 Absence from day care or school
As treated†
Primary outcome:
0.97 (0.87 to 1.08) −0.23 (−1.08 to 0.62) 8.04 7.81 URTI episodes
Secondary outcomes:
1.23 (1.18 to 1.27) 13.04 (10.69 to 15.40) 57.63 70.67 URTI days
1.12 (0.96 to 1.31) 0.42 (−0.15 to 1.00) 3.50 3.93 Severe URTI episodes
1.48 (1.41 to 1.55) 17.07 (15.16 to 18.99) 35.42 52.49 Severe URTI days
0.87 (0.75 to 1.00) −0.59 (−1.22 to 0.03) 4.54 3.94 Mild URTI episodes
0.82 (0.77 to 0.87) −4.03 (−5.40 to −2.65) 22.21 18.18 Mild URTI days
1.30 (1.20 to 1.40) 4.48 (3.26 to 5.70) 15.11 19.59 Fever days
1.07 (0.69 to 1.66) 0.03 (−0.17 to 0.24) 0.46 0.49 Middle ear complaints with fever episodes
0.98 (0.71 to 1.35) −0.02 (−0.30 to 0.26) 0.87 0.85 Middle ear complaints with fever days
1.00 (0.80 to 1.25) 0.00 (−0.41 to 0.40) 1.83 1.83 Absence from day care or school
URTI=upper respiratory tract infection.
*101 person years in adenoidectomy group, 61 in watchful waiting group.
†141 person years in adenoidectomy group, 61 in watchful waiting group.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5154 doi: 10.1136/bmj.d5154 Page 11 of 13
RESEARCHTable 6| Results for per protocol and as treated analyses adjusted for observed baseline differences for full follow-up period (maximum
24 months) in children with recurrent upper respiratory tract infections
Incidence rate ratio (95% CI) Difference in incidence rate (95% CI) Watchful waiting Adenoidectomy
Per protocol*
Primary outcome:
0.97 (0.75 to 1.26) −0.19 (−2.27 to 1.83) 8.01 7.89 URTI episodes
Secondary outcomes:
1.15 (0.81 to 1.63) 8.78 (−12.98 to 30.34) 57.44 66.23 URTI days
1.12 (0.81 to 1.60) 0.44 (−0.82 to 1.72) 3.53 3.97 Severe URTI episodes
1.38 (0.86 to 2.23) 13.19 (−6.31 to 32.62) 35.15 48.34 Severe URTI days
0.86 (0.67 to 1.08) −0.63 (−1.68 to 0.33) 4.56 3.92 Mild URTI episodes
0.80 (0.60 to 1.04) −4.58 (−10.31 to 0.72) 22.40 17.89 Mild URTI days
1.39 (0.77 to 2.45) 5.67 (−4.76 to 15.43) 14.69 20.36 Fever days
1.18 (0.50 to 3.08) 0.08 (−0.36 to 0.47) 0.44 0.52 Middle ear complaints with fever episodes
1.11 (0.41 to 3.84) 0.09 (−0.91 to 0.87) 0.81 0.90 Middle ear complaints with fever days
1.01 (0.67 to 1.56) 0.01 (−0.71 to 0.74) 1.72 1.73 Absence from day care or school
As treated†
Primary outcome:
0.96 (0.77 to 1.21) −0.31 (−2.16 to 1.47) 8.10 7.78 URTI episodes
Secondary outcomes:
1.25 (0.94 to 1.68) 14.04 (−4.35 to 31.87) 56.98 71.02 URTI days
1.08 (0.81 to 1.49) 0.29 (−0.82 to 1.39) 3.55 3.84 Severe URTI episodes
1.51 (1.02 to 2.33) 17.93 (0.34 to 34.44) 34.90 52.84 Severe URTI days
0.87 (0.70 to 1.08) −0.60 (−1.56 to 0.32) 4.54 3.94 Mild URTI episodes
0.82 (0.63 to 1.06) −3.99 (−9.48 to 1.13) 22.17 18.19 Mild URTI days
1.32 (0.78 to 2.23) 4.81 (−4.42 to 13.28) 14.90 19.71 Fever days
1.10 (0.53 to 2.63) 0.04 (−0.34 to 0.37) 0.45 0.49 Middle ear complaints with fever episodes
1.03 (0.44 to 3.30) 0.02 (−0.87 to 0.72) 0.84 0.86 Middle ear complaints with fever days
1.07 (0.75 to 1.56) 0.12 (−0.54 to 0.75) 1.75 1.87 Absence from day care or school
URTI=upper respiratory tract infection.
*101 person years in adenoidectomy group, 61 in watchful waiting group.
†141 person years in adenoidectomy group, 61 in watchful waiting group.
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RESEARCHFigures
Fig 1 Flow of participants through trial of adenoidectomy in children with recurrent upper respiratory tract infections
Fig 2 Proportion of children with upper respiratory tract infection (prevalence/week) in adenoidectomy and watchful waiting
group
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